Norwegian biotech firm Hofseth BioCare reported earnings before interest, taxes, depreciation and amortization (EBITDA) of NOK 36.7 million (€3.9 million/$4.3 million) in the first quarter of 2017 compared with losses of NOK 21.2 million (€2.3 million/$2.5 million) reported in the same period last year.
Sales came to NOK 58.6 million (€6.3 million/$6.8 million), although NOK 52.2 million (€5.6 million/$6.1 million) came from the sale of two buildings in March, the company said.
At the end of the quarter, the total assets for the company were NOK 183.1
